Document is current
Any future updates will be listed below
-
Authors
Marton, Chrystel https://orcid.org/0000-0003-4237-4652
Clémenceau, Béatrice
Dachy, Guillaume https://orcid.org/0000-0002-1668-975X
Demerle, Clémence
Derenne, Sophie
Ferrand, Christophe https://orcid.org/0000-0003-0119-3919
Giverne, Camille
Latouche, Jean-Baptiste
Lemée, Ludovic
Martinet, Jérémie https://orcid.org/0000-0002-3895-2731
Bonig, Halvard
Bensoussan, Danièle
Chabannon, Christian https://orcid.org/0000-0002-3755-4889
Köhl, Ulrike
Deschamps, Marine https://orcid.org/0000-0002-0564-0926
De Vos, John https://orcid.org/0000-0003-1880-4130
Diana, Jean-Sébastien
Dougé, Aurore
Forcade, Edouard https://orcid.org/0000-0002-8873-2868
Galaine, Jeanne
Thiant, Stéphanie
Galy, Anne
Larghero, Jérôme
Reppel, Loïc
Viel, Sébastien https://orcid.org/0000-0002-5085-443X
Boyer, Olivier https://orcid.org/0000-0002-7591-307X
Yakoub-Agha, Ibrahim
- License Information
-
More Information
Article History
Received: 18 March 2025
Revised: 7 May 2025
Accepted: 20 May 2025
First Online: 29 May 2025
Competing interests
: CM: Declares no conflict of interest. BC: Declares no conflict of interest in the field of CAR T cells. GD: Declares no conflict of interest in the field of CAR T cells. CD: Declares no conflict of interest in the field of CAR T cells. SD: Declares no conflict of interest in the field of CAR T cells. CF: shareholder and employee Advesya. CG: Declares no conflict of interest in the field of CAR T cells. JBL: Declares no conflict of interest in the field of CAR T cells. LL: Declares no conflict of interest in the field of CAR T cells. JM: Declares no conflict of interest in the field of CAR T cells. HB: Licensing fees and royalties from Medac; research support from Erydel, Miltenyi, Sandoz-Hexal (a Novartis company); honoraria and speaker fees from Medac, Miltenyi, Novartis and Terumo BCT; consultancy and membership of advisory boards for Boehringer-Ingelheim, Celgene (a BMS company), Medac, Novartis and Sandoz-Hexal; stock ownership in Healthineers. DB: Declares no conflict of interest in the field of CAR T cells. CC: received research funding and honoraria (institutional or personal) for participation in advisory boards and speakers bureau from BMS, Janssen Pharmaceuticals, Kite/Gilead, Miltenyi Biotec, Novartis. UK: received consultant and/or speaker fees from AstraZeneca, Affimed, Glycostem, GammaDelta, Zelluna, CGT manufacturing: Miltenyi Biotec and Novartis Pharma GmbH, Bristol-Myers Squibb GmbH & Co. MD: shareholder and employee Advesya. JDV: Declares no conflict of interest in the field of CAR T cells. JSD: Declares no conflict of interest in the field of CAR T cells. AD: Declares no conflict of interest in the field of CAR T cells. EF: received honoraria for participation in advisory boards and speaker’s bureau from Kite/Gilead, Novartis, Alexion, Astellas, GSK. JG: Declares no conflict of interest in the field of CAR T cells. ST: Declares no conflict of interest in the field of CAR T cells. AG: Declares no conflict of interest in the field of CAR T cells. JL: received honoraria from Novartis, Kite/Gilead, BMS, Janssen, Miltenyi Biotec. LR: Declares no conflict of interest in the field of CAR T cells. SV: Declares no conflict of interest. OB: received research funding and/or honoraria from Argenx, BMS, CSL Behring, Egle Tx. IYA: received honorarium from Novartis, BMS, KITE and Milteny Biomedecine.
